<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="MRP-1 [24,35,37,41,42]. The antiviral drugs amprenavir, nelfinavir, indinavir (PIs), and" exact="abacavir" post="(NRTI) are known as P-gp substrates [43], whereas zidovudine"/>
 <result pre="and abacavir (NRTI) are known as P-gp substrates [43], whereas" exact="zidovudine" post="and didanosine appear to be transported by MRP-4 and"/>
 <result pre="(NRTI) are known as P-gp substrates [43], whereas zidovudine and" exact="didanosine" post="appear to be transported by MRP-4 and MRP-5 [32,33,38]."/>
 <result pre="and MRP-5 [32,33,38]. Finally, zidovudine, lamivudine, abacavir, zalcitabine, stavudine, and" exact="efavirenz" post="appear as BCRP substrates [44], whereas ritonavir, saquinavir, and"/>
 <result pre="efavirenz appear as BCRP substrates [44], whereas ritonavir, saquinavir, and" exact="nelfinavir" post="are known as inhibitors of this transporter [34]. Maraviroc,"/>
 <result pre="primary human brain microvascular endothelial cells (HBMVEC) to HIV-1 and" exact="saquinavir" post="induces an increased MDR-1-mediated drug efflux [51]. Moreover, it"/>
 <result pre="efflux [51]. Moreover, it has been demonstrated that the PIs" exact="ritonavir" post="and atazinavir are able to induce P-gp expression in"/>
 <result pre="endothelial cells hCMEC/D3 demonstrated that amprenavir, atazanavir, efavirenz, ritonavir, and" exact="lopinavir" post="activate hPXR, whereas abacavir, efavirenz, and nepvirapine activate hCAR."/>
 <result pre="other words, a great number of PIs are hPXR ligands:" exact="abacavir" post="and nevirapine are hCAR ligands, and efavirenz is a"/>
 <result pre="a great number of PIs are hPXR ligands: abacavir and" exact="nevirapine" post="are hCAR ligands, and efavirenz is a ligand of"/>
 <result pre="are hPXR ligands: abacavir and nevirapine are hCAR ligands, and" exact="efavirenz" post="is a ligand of both PXR and hCAR. These"/>
 <result pre="enhancement of the cytotoxicity of some anticancer drugs induced by" exact="verapamil" post="(a vasodilator) and cyclosporin A (an immunosuppressant) was revealed."/>
 <result pre="of some anticancer drugs induced by verapamil (a vasodilator) and" exact="cyclosporin A" post="(an immunosuppressant) was revealed. These drugs were indeed able"/>
 <result pre="large and fluid binding cavity, the HIV reverse transcriptase inhibitor" exact="abacavir" post="was converted into a dimeric prodrug able to act"/>
 <result pre="cells overexpressing the efflux transporter. The tether length between the" exact="abacavir" post="molecules in the prodrug dimers was able to modulate"/>
 <result pre="strategy of antiviral drugs demonstrating that the ester conjugation of" exact="zidovudine" post="(AZT) with ursodeoxycholic acid, a bile acid which can"/>
 <result pre="drugs demonstrating that the ester conjugation of zidovudine (AZT) with" exact="ursodeoxycholic acid," post="a bile acid which can permeate the CNS, results"/>
 <result pre="Very recently, a powder formulation of agglomerates constituted by micronized" exact="ribavirin" post="and α-cyclodextrin spray-dried microparticles was nasally administered to rats."/>
 <result pre="ribavirin and α-cyclodextrin spray-dried microparticles was nasally administered to rats." exact="Ribavirin" post="accumulation in the brain obtained by this formulation was"/>
 <result pre="Regarding studies on innovative nasal formulations, the development of antiretroviral" exact="efavirenz" post="(EFV)-loaded nanoparticles based on poly(ε-caprolactone) (PCL), Eudragit® RS 100"/>
 <result pre="PVP compared to chitosan gels [104]. In addition to chitosan," exact="papaverine" post="(a phosphodiesterase inhibitor) has also been considered for its"/>
 <result pre="of nasal mucosa. In particular, after intranasal administration to rats," exact="papaverine" post="appeared to be able to induce a rapid and"/>
 <result pre="surfactant and co-surfactant, respectively, was developed for brain targeting of" exact="saquinavir" post="mesylate. This type of formulation was able to induce"/>
 <result pre="the drug in the brain after intranasal administration compared to" exact="saquinavir" post="amounts obtained after intravenous administration of plain drug suspension."/>
 <result pre="efficacy of this formulation in promoting the nose-to-brain delivery of" exact="saquinavir" post="mesylate [106]. 8.3.1. Nasal Formulations for Zidovudine Administration Several"/>
 <result pre="nose-to-brain delivery of saquinavir mesylate [106]. 8.3.1. Nasal Formulations for" exact="Zidovudine" post="Administration Several nasal formulations have been studied in order"/>
 <result pre="have been studied in order to induce the uptake of" exact="zidovudine" post="(AZT) in the central nervous system. It is well-known"/>
 <result pre="[110], resulting in a poor CNS/plasma ratio (about 0.1) of" exact="zidovudine" post="[111]. It is important to underline that AZT activity"/>
 <result pre="unwanted effects [27,115]. The first studies on nasal administration of" exact="zidovudine" post="to rats were performed using formulations constituted by an"/>
 <result pre="8.3.2. Nasal Formulations for the Administration of a Prodrug of" exact="Zidovudine" post="Recently, the prodrug UDCA-AZT, obtained by means of ester"/>
 <result pre="the prodrug UDCA-AZT, obtained by means of ester conjugation of" exact="zidovudine" post="with ursodeoxycholic acid [71], was loaded in micro-particulate nasal"/>
 <result pre="UDCA-AZT, obtained by means of ester conjugation of zidovudine with" exact="ursodeoxycholic acid" post="[71], was loaded in micro-particulate nasal formulations. This prodrug"/>
 <result pre="P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of" exact="lopinavir" post="in cultured CD4 T cells and primary human lymphocytesJ."/>
 <result pre="primary human lymphocytesJ. Antimicrob. Chemother.20076098799310.1093/jac/dkm35317890284 25.DalpiazA.FogagnoloM.FerraroL.CapuzzoA.PavanB.RassuG.SalisA.GiunchediP.GaviniE.Nasal chitosan microparticles target a" exact="zidovudine" post="prodrug to brain HIV sanctuariesAntivir. Res.201512314615710.1016/j.antiviral.2015.09.01326427553 26.NamanjaH.A.EmmertD.DavisD.A.CamposC.MillerD.S.HrycynaC.A.ChmielewskiJ.Toward eradicating HIV"/>
 <result pre="the brain: Inhibiting P-glycoprotein at the blood-brain barrier with prodrug" exact="abacavir" post="dimersJ. Am. Chem. Soc.20121342976298010.1021/ja206867t21866921 27.PavanB.DalpiazA.Prodrugs and endogenous transporters: Are"/>
 <result pre="al.ATP binding cassette multidrug transporters limit the anti-HIV activity of" exact="zidovudine" post="and indinavir in infected human macrophagesAntivir. Ther.2004951952815456083 34.GuptaA.ZhangY.UnadkatJ.D.MaoQ.HIV protease"/>
 <result pre="Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein in the transport of" exact="saquinavir" post="and indinavir in rat brain microvessel endothelial and microglia"/>
 <result pre="36.ParkS.SinkoP.J.P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of" exact="saquinavir" post="in miceJ. Pharmacol. Exp. Ther.20053121249125610.1124/jpet.104.07621615528451 37.BachmeierC.J.SpitzenbergerT.J.ElmquistW.F.MillerD.W.Quantitative assessment of HIV-1"/>
 <result pre="blood-brain barrierPharm. Res.2005221259126810.1007/s11095-005-5271-y16078135 38.EilersM.RoyU.MondalD.MRP (ABCC) transporters-mediated efflux of anti-HIV drugs," exact="saquinavir" post="and zidovudine, from human endothelial cellsExp. Biol. Med.20082331149116010.3181/0802-RM-5918535159 39.DallasS.MillerD.S.BendayanR.Multidrug"/>
 <result pre="and chemotherapyAAPS Pharm. Sci.20024E1410.1208/ps04031412423063 41.JannehO.OwenA.ChandlerB.HartkoornR.C.HartC.A.BrayP.G.WardS.A.BackD.J.KhooS.H.Modulation of the intracellular accumulation of" exact="saquinavir" post="in peripheral blood mononuclear cells by inhibitors of MRP1,"/>
 <result pre="MRP2, P-gp and BCRPAIDS2005192097210210.1097/01.aids.0000194793.36175.4016284458 42.MeadenE.R.HoggardP.G.NewtonP.TjiaJ.F.AldamD.CornforthD.LloydJ.WilliamsI.BackD.J.KhooS.H.P-glycoprotein and MRP1 expression and reduced" exact="ritonavir" post="and saquinavir accumulation in HIV-infected individualsJ. Antimicrob. Chemother.20025058358810.1093/jac/dkf16112356805 43.VaratharajanL.ThomasS.A.The"/>
 <result pre="and BCRPAIDS2005192097210210.1097/01.aids.0000194793.36175.4016284458 42.MeadenE.R.HoggardP.G.NewtonP.TjiaJ.F.AldamD.CornforthD.LloydJ.WilliamsI.BackD.J.KhooS.H.P-glycoprotein and MRP1 expression and reduced ritonavir and" exact="saquinavir" post="accumulation in HIV-infected individualsJ. Antimicrob. Chemother.20025058358810.1093/jac/dkf16112356805 43.VaratharajanL.ThomasS.A.The transport of"/>
 <result pre="for HIVDrug Metab. Dispos.20053358759510.1124/dmd.104.00262615650075 46.WalkerD.K.BowersS.J.MitchellR.J.PotchoibaM.J.SchroederC.M.SmallH.F.Preclinical assessment of the distribution of" exact="maraviroc" post="to potential human immunodeficiency virus (HIV) sanctuary sites in"/>
 <result pre="Biotechnol.20077627928610.1007/s00253-007-1017-617522856 49.OwenA.JannehO.HartkoornR.C.ChandlerB.BrayP.G.MartinP.WardS.A.HartC.A.KhooS.H.BackD.J.In vitro synergy and enhanced murine brain penetration of" exact="saquinavir" post="coadministered with mefloquineJ. Pharmacol. Exp. Ther.20053141202120910.1124/jpet.105.08627215923343 50.KruhG.D.BelinskyM.G.The MRP family"/>
 <result pre="following co-exposure to HIV-1 and saquinavirPLoS ONE20138e7537410.1371/journal.pone.007537424098380 52.PerloffM.D.von MoltkeL.L.GreenblattD.J.Ritonavir and" exact="dexamethasone" post="induce expression of CYP3A and P-glycoprotein in ratsXenobiotica20043413315010.1080/0049825031000163021514985144 53.PerloffM.D.von"/>
 <result pre="in ratsXenobiotica20043413315010.1080/0049825031000163021514985144 53.PerloffM.D.von MoltkeL.L.FaheyJ.M.GreenblattD.J.Induction of P-glycoprotein expression and activity by" exact="ritonavir" post="in bovine brain microvessel endothelial cellsJ. Pharm. Pharmacol.20075994795310.1211/jpp.59.7.000617637189 54.ZastreJ.A.ChanG.N.Y.RonaldsonP.T.RamaswamyM.CouraudP.O.RomeroI.A.WekslerB.BendayanM.BendayanR.Up-regulation"/>
 <result pre="molecular basis for poly-specific drug bindingScience20093231718172210.1126/science.116875019325113 70.NamanjaH.A.EmmertD.HrycynaC.A.ChmielewskiJ.Homodimers of the antiviral" exact="abacavir" post="as modulators of P-glycoprotein transport in cell culture: Probing"/>
 <result pre="P-glycoprotein transport in cell culture: Probing tether lengthMedchemcomm201341344134910.1039/c3md00196b24273637 71.DalpiazA.PaganettoG.PavanB.FogagnoloM.MediciA.BeggiatoS.PerroneD.Zidovudine and" exact="ursodeoxycholic acid" post="conjugation: Design of a new prodrug potentially able to"/>
 <result pre="of PLGA nanoparticles as delivery systems of a prodrug of" exact="zidovudine" post="obtained by its conjugation with ursodeoxycholic acidDrug Deliv.201421221123210.3109/10717544.2013.84474424134683 73.DalpiazA.FerraroL.PerroneD.LeoE.IannuccelliV.PavanB.PaganettoG.BeggiatoS.ScaliaS.Brain"/>
 <result pre="its conjugation with ursodeoxycholic acidDrug Deliv.201421221123210.3109/10717544.2013.84474424134683 73.DalpiazA.FerraroL.PerroneD.LeoE.IannuccelliV.PavanB.PaganettoG.BeggiatoS.ScaliaS.Brain uptake of a" exact="Zidovudine" post="prodrug after nasal administration of solid lipid microparticlesMol. Pharm.2014111550156110.1021/mp400735c24717116"/>
 <result pre="virus type 1 encephalitisJ. Infect. Dis.200819866467210.1086/59067118662130 84.EliaG.BelloliC.CironeF.LucenteM.S.CarusoM.MartellaV.DecaroN.BuonavogliaC.OrmasP.In vitro efficacy of" exact="ribavirin" post="against canine distemper virusAntivir. Res.20087710811310.1016/j.antiviral.2007.09.00417949825 85.ColomboG.LorenziniL.ZironiE.GalligioniV.SonvicoF.BalducciA.G.PagliucaG.GiulianiA.CalzàL.ScagliariniA.Brain distribution of ribavirin"/>
 <result pre="of ribavirin against canine distemper virusAntivir. Res.20087710811310.1016/j.antiviral.2007.09.00417949825 85.ColomboG.LorenziniL.ZironiE.GalligioniV.SonvicoF.BalducciA.G.PagliucaG.GiulianiA.CalzàL.ScagliariniA.Brain distribution of" exact="ribavirin" post="after intranasal administrationAntivir. Res.20119240841410.1016/j.antiviral.2011.09.01222001322 86.GiulianiA.BalducciA.G.ZironiE.ColomboG.BortolottiF.LorenziniL.GalligioniV.PagliucaG.ScagliariniA.CalzàL.et al.In vivo nose-to-brain delivery"/>
 <result pre="Res.20119240841410.1016/j.antiviral.2011.09.01222001322 86.GiulianiA.BalducciA.G.ZironiE.ColomboG.BortolottiF.LorenziniL.GalligioniV.PagliucaG.ScagliariniA.CalzàL.et al.In vivo nose-to-brain delivery of the hydrophilic antiviral" exact="ribavirin" post="by microparticle agglomeratesDrug Deliv.20182537638710.1080/10717544.2018.142824229382237 87.MistryA.StolnikS.IllumL.Nanoparticles for direct nose-to-brain delivery"/>
 <result pre="drugsInt. J. Pharm.200937914615710.1016/j.ijpharm.2009.06.01919555750 88.HoekmanJ.D.HoR.J.Effects of localized hydrophilic mannitol and hydrophobic" exact="nelfinavir" post="administration targeted to olfactory epithelium on brain distributionAAPS PharmSciTech.20111253454310.1208/s12249-011-9614-121519984"/>
 <result pre="the sheep nasal cavityInt. J. Pharm.200121718319110.1016/S0378-5173(01)00602-011292554 98.ZakiN.M.AwadG.A.MortadaN.D.Abd ElhadyS.S.Enhanced bioavailability of" exact="metoclopramide" post="HCl by intranasal administration of a mucoadhesive in situ"/>
 <result pre="acyclovirDrug Dev. Ind. Pharm.20093535236210.1080/0363904080236051018770068 105.KrishanM.GudelskyG.A.DesaiP.B.GenterM.B.Manipulation of olfactory tight junctions using" exact="papaverine" post="to enhance intranasal delivery of gemcitabine to the brainDrug"/>
 <result pre="to the brainDrug Deliv.20142181610.3109/10717544.2013.84001724116937 106.MahajanH.S.MahajanM.S.NerkarP.P.AgrawalA.Nanoemulsion-based intranasal drug delivery system of" exact="saquinavir" post="mesylate for brain targetingDrug Deliv.20142114815410.3109/10717544.2013.83801424128122 107.PardridgeW.M.Blood-brain barrier drug targeting:"/>
 <result pre="of brain drug developmentMol. Interv.200339010510.1124/mi.3.2.9014993430 108.WongS.L.Van BelleK.SawchukR.J.Distributional transport kinetics of" exact="zidovudine" post="between plasma and brain extracellular fluid/cerebrospinal fluid in the"/>
 <result pre="brain during intravenous and intracerebroventricular infusionJ. Pharm. Sci.1995787187610.1002/jps.2600840717 111.WongS.L.WangY.SawchukR.J.Analysis of" exact="zidovudine" post="distribution to specific regions in rabbit brain using microdialysisPharm."/>
 <result pre="fluid cisterns via subarachnoid velae in ratNeuroscience1996751271128810.1016/0306-4522(96)00281-38938759 114.SekiT.SatoN.HasegawaT.KawaguchiT.JuniK.Nasal absorption of" exact="zidovudine" post="and its transport to cerebrospinal fluid in ratsPharm. Bull.1994171135113710.1248/bpb.17.1135"/>
 <result pre="oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal" exact="zidovudine" post="delivery to the brainInt. J. Pharm.20114111910.1016/j.ijpharm.2011.02.04021356294 117.Al-GhananeemA.M.SmithM.CoronelM.L.TranH.Advances in brain"/>
 <result pre="Protein MRP-1 ABCC1 hydrophilic anion compounds, large molecules saquinavir, ritonavir," exact="lopinavir" post="paclitaxel, probenecid, MK-571 MRP-4 MRP-5 ABCC4 ABCC5 small polar"/>
 <result pre="MRP-4 MRP-5 ABCC4 ABCC5 small polar compounds, nucleoside analogues Zidovudine," exact="didanosine" post="Breast-Cancer-Resistance Protein BRCP ABCG2 partially overlap with those of"/>
 <result pre="P-gp zidovudine, lamivudine, abacavir, zalcitabine, stavudine, efavirenz, dolutegravir ritonavir, saquinavir," exact="nelfinavir" post=""/>
</results>
